Lauren Barnes Joins Ossium Health's Board of Directors [Yahoo! Finance]
Blueprint Medicines Corporation (BPMC)
Last blueprint medicines corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
blueprintmedicines.com
Company Research
Source: Yahoo! Finance
marrow banking platform, today announced the appointment of Lauren Barnes to its Board of Directors. Barnes brings extensive experience in healthcare product commercialization, significantly bolstering Ossium's capacity to drive growth and deliver life-changing solutions for patients suffering from hematologic diseases, organ transplant rejection, and musculoskeletal defects. "Lauren's expertise and proven track record in biopharmaceutical commercialization are invaluable assets," said Kevin Caldwell, Ossium's CEO, Co-Founder & President. "Her insights and guidance will be instrumental in bringing our products to the patients that need them as we transition to a commercial company." Barnes boasts a distinguished career in commercialization, pricing, reimbursement, market access, and managed markets for healthcare products spanning various market segments. She currently serves as Senior Vice President of Strategic Market Development & Access at Blueprint Medicines, a global commerc
Show less
Read more
Impact Snapshot
Event Time:
BPMC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BPMC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BPMC alerts
High impacting Blueprint Medicines Corporation news events
Weekly update
A roundup of the hottest topics
BPMC
News
- Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at Stifel Nicolaus from $120.00 to $130.00. They now have a "buy" rating on the stock.MarketBeat
- Blueprint Medicines Co. (NASDAQ: BPMC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $110.00 price target on the stock.MarketBeat
- Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $97.00 price target on the stock.MarketBeat
- Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $125.00 price target on the stock.MarketBeat
- Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release [Yahoo! Finance]Yahoo! Finance
BPMC
Earnings
- 2/15/24 - Beat
BPMC
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEF
- 4/25/24 - Form 8-K
- BPMC's page on the SEC website